

Edgar Filing: Genesis Pharmaceuticals Enterprises, Inc. - Form SC 13G

Genesis Pharmaceuticals Enterprises, Inc.

Form SC 13G

November 16, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
Under the Securities Exchange Act of 1934  
(Amendment No. \_\_\_\_\_)

Genesis Pharmaceuticals Enterprises, Inc. (Name of Issuer)

Common (Title of Class of Securities)

37184Q 10 2 (CUSIP Number)

11/07/07 (Date of Event Which Requires Filing of  
this Statement)

Check the appropriate box to designate the rule  
pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\*The remainder of this cover page shall be filled out  
for a reporting persons initial filing on this form  
with respect to the subject class of securities, and  
for any subsequent amendment containing information  
which would alter the disclosures provided in a prior  
cover page.

The information required in the remainder of this cover  
page shall not be deemed to be filed for the purpose  
of Section 18 of the Securities Exchange Act of 1934  
(Act) or otherwise subject to the liabilities of that  
section of the Act but shall be subject to all other  
provisions of the Act (however see the Notes).

CUSIP No. 37184Q 10 2

1.  
Names of Reporting Persons. Pope Asset Management, LLC  
I.R.S. Identification Nos. of above persons 62-1871308

2.  
Check the Appropriate Box if a Member of a Group

(a)  
(b)

3.  
SEC Use Only

4.  
Citizenship or Place of Organization TennesseeNumber of

Edgar Filing: Genesis Pharmaceuticals Enterprises, Inc. - Form SC 13G

Shares  
Beneficially  
Owned by  
Each Reporting  
Person With

5.  
Sole Voting Power 30000000

6.  
Shared Voting Power 0

7.  
Sole Dispositive Power 30000000

8.  
Shared Dispositive Power 0

9.  
Aggregate Amount Beneficially Owned by Each  
Reporting Person 30000000

10.  
Check if the Aggregate Amount in Row (9) Excludes Certain Shares

11.  
Percent of Class Represented by Amount in Row (9) 7.67

12.  
Type of Reporting Person (See Instructions) IA

1.  
Names of Reporting Persons. Pope Investments, LLC  
I.R.S. Identification Nos. of above persons 260281944

2.  
Check the Appropriate Box if a Member of a Group

(a)  
(b)

3.  
SEC Use Only

4.  
Citizenship or Place of Organization DelawareNumber of

Shares  
Beneficially  
Owned by  
Each Reporting  
Person With

5.  
Sole Voting Power 30000000

6.  
Shared Voting Power 0

7.  
Sole Dispositive Power 30000000

8.  
Shared Dispositive Power 0

Edgar Filing: Genesis Pharmaceuticals Enterprises, Inc. - Form SC 13G

9.  
Aggregate Amount Beneficially Owned by Each  
Reporting Person 30000000  
10.  
Check if the Aggregate Amount in Row (9) Excludes Certain Shares  
11.  
Percent of Class Represented by Amount in Row (9) 7.67  
  
12.  
Type of Reporting Person (See Instructions) 00

1.  
Names of Reporting Persons. William P. Wells  
I.R.S. Identification Nos. of above persons 426961338

2.  
Check the Appropriate Box if a Member of a Group

(a)  
(b)

3.  
SEC Use Only

4.  
Citizenship or Place of Organization Tennessee  
Number of  
Shares  
Beneficially  
Owned by  
Each Reporting  
Person With

5.  
Sole Voting Power 30000000

6.  
Shared Voting Power 0

7.  
Sole Dispositive Power 30000000

8.  
Shared Dispositive Power 0

9.  
Aggregate Amount Beneficially Owned by Each  
Reporting Person 30000000  
10.  
Check if the Aggregate Amount in Row (9) Excludes Certain Shares  
11.  
Percent of Class Represented by Amount in Row (9) 7.67

12.  
Type of Reporting Person (See Instructions) IN

Item 1.

(a)

## Edgar Filing: Genesis Pharmaceuticals Enterprises, Inc. - Form SC 13G

Name of Issuer Genesis Pharmaceuticals Enterprises, Inc.

(b)

Address of Issuer's Principal Executive Offices  
Middle Section, Longmao Street, Area A, Laiyang  
Waixiangxing Industrial Park Laiyang City, Yanti, Shandong Province,  
People's Republic of China 71005

Item 2.

(a)

This statement is filed by and on behalf of:  
Pope Investments LLC a Delaware limited liability company  
Pope Asset Management LLC a Tennessee limited  
liability company and William P. Wells. Pope Asset serves and an  
investment adviser and/or manager to various persons,  
including Pope Investments. Pope Asset is the sole  
manager for Pope Investments and has sole voting  
control and investment and disposition power and discretion  
with respect to all securities held by Pope Investments.  
Pope Asset may be deemed to beneficially own shares owned and/or  
held by and for the account of and/or benefit of various persons,  
including Pope Investments. Mr. Wells is the sole manager of Pope Asset.  
Mr. Wells may be deemed to own shares owned and/or held by and/or for the  
account of and/or benefit of Pope Investments. Each of the reporting  
persons declares that neither the filing of this statement nor anything  
herein shall be construed as an admission that such reporting person is,  
for the purposes of Section 13(d) or 13(g) of the Act or any other  
purpose, the beneficial owner of any securities covered by this statement.  
Each of the reporting persons may be deemed to be a member of a group  
with respect to the issuer or securities of the issuer for the  
purposes of Section 13(d) or 13(g) of the Act.  
Each of the reporting persons declares that neither the  
filing of this statement nor anything herein shall be construed  
as an admission that such person is, for  
the purposes of Section 13(d) or 13(g) of the Act or any  
other purpose, (i) acting (or has agreed or is agreeing to act  
together with any other person) as a partnership, limited  
partnership, syndicate, or other group for the purpose of acquiring,  
holding, or disposing of securities of the issuer or otherwise  
with respect to the issuer or any securities of the issuer,  
or (ii) a member of any group with respect to the issuer or any  
securities of the issuer. Pope Investments, Pope Asset and Mr. Wells  
have entered into a Joint Filing Agreement, a copy of which is  
filed with this statement as Exhibit 99.1, pursuant to which  
they have agreed to file this Schedule 13G jointly in accordance  
with the provisions of Rule 13d-1(k) of the Act.

(b)

Address of Principal Business Office or if none,  
Residence 5100 Poplar Ave Ste 805 Memphis TN 38137

(c)

Citizenship USA

(d)

Title of Class of Securities Common

(e)

CUSIP Number 37184Q102

Edgar Filing: Genesis Pharmaceuticals Enterprises, Inc. - Form SC 13G

Item 3.

If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c) check whether the person filing is a:

(a)  
Not applicable.

Item 4.

Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Explanatory Notes. For purposes of determining the percentage of outstanding shares with respect to this statement the reporting persons have relied upon information obtained from the issuer that the aggregate number of outstanding shares of Common Stock of the issuer on November 6 2007, prior to the acquisition for which this schedule is filed, was 391378760. The number of shares of Common Stock reported herein includes 20000000 shares of Common Stock issuable upon conversion of 5 Million dollars aggregate principal amount of the Issuer's 6 percent Convertible Debentures due November 30, 2010 and 10000000 shares of Common Stock issuable upon exercise of Warrants issued in connection with the 6 percent Convertible Debentures. Pope Investments acquired the Convertible Debentures and Warrants pursuant to a Stock Purchase Agreement dated November 6, 2007.

(a) Amount Beneficially Owned:  
See Item 9 of each cover page for the respective reporting persons.

(b) Percent of Class:  
See Item 11 of each cover page for the respective reporting persons.

(c) Number of shares as to which the person has:

(i) Sole power to vote or direct the vote:  
See Item 5 of each cover page for the respective reporting persons.

(ii) Shared power to vote or to direct the vote:  
See Item 6 of each cover page for the respective reporting persons.

(iii) Sole power to dispose or direct the disposition of:  
See Item 7 of each cover page for the respective reporting persons.

(iv) Shared power to dispose or to direct the disposition of:  
See Item 8 of each cover page for the respective reporting persons. Pope Asset and Mr. Wells do not directly own any shares of the issuer's Common Stock. Pope Asset is the sole Manager of Pope Investments. Mr. Wells is the Manager of Pope Asset. Pope Asset may be deemed to beneficially own shares owned and/or held by and for the account of and/or benefit of various persons, including Pope Investments. Mr. Wells may be deemed to own shares owned and/or held by and/or for the account of and/or

Edgar Filing: Genesis Pharmaceuticals Enterprises, Inc. - Form SC 13G

benefit of Pope Investments.

Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such reporting person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [    ].

Instruction: Dissolution of a group requires a response to this item.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

Pope Asset serves as an investment adviser and/or manager to various persons, including Pope Investments. Pope Asset is the sole manager for Pope Investments and has sole voting control and investment and disposition power and discretion with respect to all securities held by Pope Investments. Pope Asset may be deemed to beneficially own shares owned and/or held by and for the account of and/or benefit of various persons, including Pope Investments. Mr. Wells is the sole manager of Pope Asset. Mr. Wells may be deemed to own shares owned and/or held by and/or for the account of and/or benefit of Pope Investments.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

Item 8.

Identification and Classification of Members of the Group

## Edgar Filing: Genesis Pharmaceuticals Enterprises, Inc. - Form SC 13G

If a group has filed this schedule pursuant to 240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to 240.13d-1(c) or 240.13d-1(d), attach an exhibit stating the identity of each member of the group.

### Item 9.

#### Notice of Dissolution of Group

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

### Item 10.

#### Certification

##### (a)

The following certification shall be included if the statement is filed pursuant to 240.13d-1(b):  
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

11/16/07 Date

William P. Wells Signature

William P. Wells/President Name/Title

Pope Asset Management, LLC William P. Wells Signature

Pope Investments, LLC William P. Wells Signature

Exhibit 99.1

#### JOINT FILING AGREEMENT

This will conform the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, \$.001 par value, of Genesis Pharmaceuticals Enterprises, Inc., a Florida corporation, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in a accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: November 16, 2007

Edgar Filing: Genesis Pharmaceuticals Enterprises, Inc. - Form SC 13G

Pope Investments, LLC William P. Wells Signature  
William P. Wells/President Name/Title  
Pope Asset Management, LLC, William P. Wells Signature  
Willaim P. Wells/Manager Willaim P. Wells Signature  
WILIAM P. WELLS Signature  
William P. Wells, Individually